New relationship aims to
explore broad-based applications for Rockley’s non-invasive
biomarker sensing platform in research projects
Rockley Photonics (NYSE: RKLY), a global leader in
photonics-based health monitoring and communications solutions,
formed a strategic relationship to incorporate Rockley’s
non-invasive biomarker sensing platform into potential clinical and
healthcare research studies. Rockley will be working with the Icahn
School of Medicine at Mount Sinai in New York, NY, part of the
Mount Sinai Health System, for potential collaboration in future
research studies.
The initiative aims to incorporate the next generation of
non-invasive biomarker sensing in a series of studies to evaluate
the use of wristbands and other wearables for a variety of
potential applications, including remote monitoring and diagnosis.
Rockley aims to create new opportunities for its photonics-based
sensing platform in healthcare and medical applications and help
expand the future use of real-time, non-invasive biomarker sensing
for people around the globe.
“At Mount Sinai, we pride ourselves on our full-spectrum
healthcare activities and relentless pursuit of leveraging the
latest cutting-edge technologies in our research,” said Zahi A.
Fayad, director of the BioMedical Engineering and Imaging
Institute, at the Icahn School of Medicine at Mount Sinai. “We look
forward to designing studies that evaluate the application of
mobile, non-invasive sensing capabilities and examine the ability
to identify biomarker correlations. The results have the potential
for real and substantial impact in mobile health and clinical
care.”
“We are honored and delighted to incorporate our unique
biomarker sensing technology in what could be many exciting and
truly eye-opening research studies,” said Dr. Andrew Rickman, chief
executive officer and founder of Rockley Photonics. “The learnings
gained from these studies have the potential to accelerate the
development of new algorithms and applications in remote
healthcare, from real-time biomarker measurement to early disease
state identification. By enabling these new capabilities on a small
wearable device, we expect to bring easier access to key health
insights to larger and more diverse populations.”
Rockley’s sensing platform enables clinical and healthcare
research practitioners to integrate more comprehensive non-invasive
biomarker measurements in their remote monitoring studies.
Rockley’s patented silicon photonics-based laser technology
significantly expands the range of biomarkers that can be detected
and measured by current LED-based sensors. This expanded range
includes key biomarkers like core body temperature, blood pressure,
body hydration, alcohol, lactate, and glucose trends, among others.
These new measurement capabilities have the potential to transform
digital healthcare by providing real-time insights into a variety
of health conditions and by enabling early detection of multiple
disease states.
More information about Rockley’s digital health monitoring
solution is available here:
https://rockleyphotonics.com/biomarker-sensing
About Rockley Photonics
A global leader in photonics-based health monitoring and
communications solutions, Rockley Photonics is developing a
comprehensive range of photonic integrated circuits and associated
modules, sensors, and full-stack solutions. From next-generation
sensing platforms specifically designed for mobile health
monitoring and machine vision to high-speed, high-volume solutions
for data communications, Rockley is laying the foundation for a new
generation of applications across multiple industries. Rockley
believes that photonics will eventually become as pervasive as
micro-electronics, and it has developed a platform with the power
and flexibility needed to address both mass markets and a wide
variety of vertical applications.
Formed in 2013, Rockley is uniquely positioned to support
hyper-scale manufacturing and address a multitude of high-volume
markets. Rockley has partnered with numerous tier-1 customers
across a diverse range of industries to deliver the complex optical
systems required to bring transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release that are not historical facts
constitute “forward-looking statements” for purposes of the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include statements
regarding Rockley’s future expectations, beliefs, plans,
objectives, and assumptions regarding future events or performance.
The words “accelerate,” “advance,” “aim” “anticipate,” “believe,”
“can,” “continue,” “could,” “developing,” “enable,” “estimate,”
“eventual,” “expand, “expect,” “focus,” “future,” “goal,” “intend,”
“may,” “might,” “opportunity,” “outlook,” “plan,” “possible,”
“position,” “potential,” “predict,” “project,” “revolutionize,”
“seem,” “should,” “trend,” “vision,” “will,” “would” or other terms
that predict or indicate future events, trends, or expectations,
and similar expressions or the negative of such expressions may
identify forward-looking statements, but the absence of these words
or terms does not mean that a statement is not forward-looking.
Forward-looking statements in this press release include, but are
not limited to, statements regarding the following: (a) the
anticipated focus, aspects, and benefits of Rockley’s new strategic
relationship and research initiative with Mount Sinai, including:
(i) the exploration of broad-based applications for Rockley’s
non-invasive biomarker sensing platform in research projects,
potential collaboration in future research studies with the Icahn
School of Medicine at Mount Sinai, and the incorporation of
Rockley’s non-invasive biomarker sensing platform into potential
clinical and healthcare research studies; (ii) the aim to
incorporate the next generation of non-invasive biomarker sensing
in studies to evaluate the use of wearables for potential
applications, including remote monitoring and diagnosis, (iii) the
potential creation of opportunities for the sensing platform in
healthcare and medical applications and to help expand the future
use of real-time, non-invasive biomarker sensing, (iv) the design
of studies that evaluate the application of mobile, non-invasive
sensing capabilities and examine the ability to identify biomarker
correlations and the potential impact thereof on mobile health and
clinical care, (v) the potential to accelerate the development of
new algorithms and applications in remote healthcare, and (vi) the
ability to bring easier access to key health insights and broader
participation to larger, more diverse populations by enabling such
capabilities; (b) the ability of the sensing platform to enable
practitioners to integrate more comprehensive non-invasive
biomarker measurements in remote monitoring studies; (c) the
potential for Rockley’s patented silicon photonics-based laser
technology to expand the range of biomarkers that can be detected
and measured by current LED-based sensors; (d) the potential of
such new measurement capabilities to transform digital healthcare
by providing real-time insights about a variety of health
conditions and enabling early detection of multiple disease states;
(e)the anticipated and potential features and benefits of Rockley’s
platform, products, and technology, including its digital health
monitoring solution; (f) its development of a range of photonic
integrated circuits and associated modules, sensors, and full-stack
solutions; (g) Rockley’s belief that photonics will eventually
become as pervasive as micro-electronics; and (h) Rockley’s
potential to support hyper-scale manufacturing, address a multitude
of high-volume markets, and deliver the complex optical systems
required to bring transformational products to market.
Forward-looking statements are subject to several risks and
uncertainties (many of which are beyond Rockley’s control) or other
assumptions that may cause actual results or performance to differ
materially from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the following: (i) Rockley’s ability to achieve
customer acceptance and commercial production of its products and
technology, including in a timely and cost-effective manner; (ii)
Rockley’s ability to achieve customer design wins and convert
memoranda of understanding and development contracts into
production contracts; (iii) risks related to purchase orders,
including the lack of long-term purchase commitments, the
cancellation, reduction, delay, or other changes in customer
purchase orders, and if and to the extent customers seek to enter
into licensing arrangements in lieu of purchases; (iv) Rockley’s
history of losses and need for additional capital and its ability
to access additional financing to support its operations and
execute on its business plan, as well as the risks associated
therewith; (v) legal and regulatory risks; (vi) risks associated
with its fabless manufacturing model and dependency on third-party
suppliers; (vii) Rockley’s reliance on a few significant customers
for a majority of its revenue and its ability to expand and
diversify its customer base; (viii) Rockley’s financial
performance; (ix) the impacts of COVID-19 on Rockley, its customers
and suppliers, its target markets, and the global economy; (x)
Rockley’s ability to successfully manage growth and its operations
as a public company; (xi) fluctuations in Rockley’s stock price and
Rockley’s ability to maintain the listing of its ordinary shares on
the NYSE; (xii) Rockley’s ability to anticipate and respond to
industry trends and customer requirements; (xiii) changes in the
current and future markets in which Rockley is or may be engaged;
(xiv) risks related to competition and intellectual property; (xv)
market opportunity and demand for Rockley’s products and
technology, as well as the customer products into which Rockley’s
products and technology are incorporated; (xvi) risks related to
international operations; (xvii) risks related to cybersecurity,
privacy, and infrastructure; (xviii) risks related to financial and
accounting matters; (xix) general economic, financial, political,
and business conditions, both domestic and foreign; (xx) Rockley’s
ability to realize the anticipated benefits of its recently
completed business combination with SC Health Corporation; and
(xxi) Rockley’s ability to realize the anticipated benefits of
strategic relationships, including with Mount Sinai, as well as
other factors described under the heading “Risk Factors” in
Rockley’s quarterly report on Form 10-Q for the quarter ended
September 30, 2021, and in other documents Rockley files with the
Securities and Exchange Commission in the future.
The forward-looking statements contained in this press release
are based on various assumptions, whether or not identified in this
press release, and on Rockley’s current expectations, beliefs, and
assumptions and are not predictions of actual performance. If any
of these risks or uncertainties materialize, or should any of these
assumptions prove incorrect, actual results may differ materially
from those discussed in or implied by these forward-looking
statements. There can be no assurance that future developments
affecting Rockley will be those that have been anticipated. These
forward-looking statements speak only as of the date hereof and
Rockley does not intend to update or revise any forward-looking
statements, whether because of new information, future events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211118005630/en/
Media Karen Boud Resonates Telephone: +44 (0) 1635 898 698
Email: rockley@resonates.com
Investors Gwyn Lauber Rockley Photonics Email:
investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Apr 2023 to Apr 2024